Lumikha ang Food and Drug Administration (FDA) ng isang task force upang pabilisin ang paglalabas ng Covid-19 drugs sa Philippine market at matiyak na magiging mas accessible ito para sa mga mamamayan.
Sa isang pahayag, sinabi ni FDA Director General Samuel Zacate na makatutulong ang Task Force Fleming para mapabilis ang pag-apruba at ebalwasyon sa Covid-19 drugs, nang hindi naisasakripisyo ang bisa, kalidad at kaligtasan nito.
Matatandaang naglabas na ang state drug regulator ng emergency use authorizations para sa mga gamot at bakuna laban sa Covid-19 na may ilang kondisyon.
"Now, with the introduction of Task Force Fleming, Covid-19 drugs that will be approved and issued with Certificates of Product Registration will be readily accessible to the public in FDA-licensed drug establishments with the assurance that any post-market issues will be addressed through more rigorous surveillance and pharmacovigilance," paliwanag ni Zacate.
Romualdez, nanawagan sa Kamara: 'Let us reject baseless accusations!'
Nabatid na sa kasalukuyan ay may apat nang Covid-19 drugs na nabigyan ng EUA ang nakapagsumite ng aplikasyon para sa CPR.
Hinikayat rin ni Zacate ang mga pharmaceutical companies na mag-aplay na rin ng CPR.
Sinegundahan naman ito ni Department of Health (DOH) officer-in-charge Maria Rosario Vergeire at sinabing, "We welcome FDA’s efforts to institutionalize this initiative that will focus on processing the registration of Covid-19 drugs and to make them available commercially."
"We also encourage manufacturers or suppliers to transition their Covid-19 EUAs into a product registration as this will be a good start to our economic recovery," aniya pa.
